111In-ETN029

N/A

Report date: 2025/11/21 17:16:22
NME

Base Information

Drug Name111In-ETN029
Drug Alias Name111In-ETN029
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Indium > 111InRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionDelta-like protein 3 modulators
TargetsDelta-like protein 3
Therapy Area/IndicationsGastroenteropancreatic neuroendocrine tumorProstatic NeoplasmsSmall Cell Lung Carcinoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag
Inactive CompaniesN/A
Active IndicationsGastroenteropancreatic neuroendocrine tumorProstatic NeoplasmsSmall Cell Lung Carcinoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A